Bristol’s Yervoy falls short in prostate cancer study

By Ransdell Pierson (Reuters) – Bristol-Myers Squibb Co’s immunotherapy drug Yervoy failed to significantly prolong survival among patients with advanced prostate cancer who had previously received chemotherapy, according to limited data from the first late-stage study of the drug for the condition. Yervoy (ipilimumab) frees the immune system to attack and kill cancer cells by blocking the action of a protein called CTLA-4. …